Gyre Therapeutics Inc recorded a cumulative net loss of $-17 million during 12 month ending in the second quarter 2026.
The Healthcare sector has seen employees of 72 other companies achieving higher income per employee. While Gyre Therapeutics Inc 's total ranking has deteriorated compared to the previous quarter from 2379 to 2382.

What is Income per Employee Ratio?

Select the Comparisons :

None ▼

Select the Ratio:

Net Income per Employee▼

None ▼

Net Income per Employee▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

GYRE Net Income per Employee	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Net Income Change	-	-	-	107.84 %	-65.27 %
Net Income per Employee (TTM) $	-27,871	-2,230	15,987	19,165	14,181
GYRE's Total Ranking	# 2382	# 2379	# 1762	# 259	# 251
Seq. Net Income Change	-	-	-	276.65 %	-57.79 %

GYRE Company Profile >> Back to GYRE Efficiency Comparisons >> Compare GYRE Net Income per Employee to its Competitors

GYRE Net Income per Employee Company Ranking
Within:	No.
Major Pharmaceutical Preparations Industry	# 73
Healthcare Sector	# 214
Overall Market	# 2382

Net Income per Employee Statistics
High	Average	Low
$ 129,371	$ -35,776	$ -142,286
(Mar 31 2023)		(Dec 31 2021)

News about Gyre Therapeutics Inc Income per employee

Gyre Therapeutics Achieves Milestones with NMPA Clearance for Pirfenidone Clinical Trials and Strategic Leadership Ex...

Gyre Therapeutics, a pioneering biopharmaceutical company at the forefront of addressing complex medical challenges, has reached significant milestones in its quest for innovative healthcare solutions. In a decisive move, Gyre Therapeutics recently announced that it has received approval from China’s National Medical Products Administration (NMPA) to commence clinical trials evaluating the efficacy of Pirfenidone capsules in treating oncology-related pulmonary complications. This strategic development is poised to amplify the company s footprint in the realm of pharmaceutical innovations, specifically targeting critical health concerns stemming from cancer treatments.Pirfenidone, a well-regarded antifibrotic agent, is commonly employed in treating idiopathic pulmonary fibrosis. The green light from NMPA marks a pivotal step in diversifying Pirfenidone’s therapeutic applications. The clinical trial aims to assess its potential benefits in mitigating or even reversing pulmonary deterioration caused by certain oncology treatments. By delving into this innovative application, Gyre Therapeutics stands on the cusp of addressing unmet needs in oncology care, potentially improving the quality of life for patients experiencing respiratory complications as a result of their cancer therapy.

Companies with similar Income per Employee for 12 month ending Jun 30 2026, within Healthcare Sector

Income per Employee

Income 12 month ending Jun 30 2026

Number of Employees Jun 30 2026

Date modified: 2026-08-14T20:17:45+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.